By Fineline Cube 
Zhifei Biological (SHE: 300122) announced on April 1, 2025, that its subsidiary Zhifei Longcom has received approval from the National Medical Products Administration (NMPA) for the clinical trial of its trivalent influenza virus split vaccine (ZFA02 adjuvant). This approval marks a significant step forward in the development of the vaccine, which is designed to prevent influenza caused by specific strains of the virus.
Vaccine Innovation
The trivalent influenza vaccine developed by Zhifei Longcom includes an adjuvant, which is intended to enhance the body’s immune response to the vaccine. Currently, there are no adjuvanted influenza vaccines officially approved for marketing in China, highlighting the potential for this product to address an unmet medical need.
Global Context
While Seqirus’ adjuvanted influenza vaccine has been approved and is in use overseas, Zhifei Bio’s approval represents a notable advancement in the domestic vaccine landscape. This development positions Zhifei to potentially become a key player in the Chinese market for influenza prevention.-Fineline Info & Tech